GLP-1 Prescriptions for Sleep Apnea: The Zepbound OSA Pathway

The OSA Approval Changes the Insurance Equation

The FDA approval of tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea in adults with obesity opened a prescription pathway that didn't exist before. For patients who have both OSA and obesity, this approval creates an opportunity: insurance coverage for GLP-1 therapy through the sleep apnea indication, even when the weight management indication isn't covered.

This is significant because many insurance plans that exclude anti-obesity medications still cover medications for sleep apnea. The same drug, prescribed for a different indication, may receive coverage that was previously denied.

Eligibility for the OSA Pathway

To use the OSA prescribing pathway, you need: a diagnosis of moderate-to-severe obstructive sleep apnea (AHI ≥ 15 on a sleep study, or AHI ≥ 5 with symptoms), a BMI ≥ 30 (obesity), and a prescriber willing to prescribe Zepbound under the OSA indication. Your sleep study documentation is the key clinical evidence.

If you suspect you have sleep apnea but haven't been formally diagnosed, a sleep study is the first step. Home sleep tests (HSTs) are widely available through primary care and can confirm the diagnosis without an overnight sleep lab visit.

Insurance Coverage Under the OSA Indication

When Zepbound is prescribed for sleep apnea, the prior authorization submission uses different diagnosis codes (G47.33 for OSA) rather than obesity codes. The clinical documentation emphasizes sleep apnea severity, CPAP adherence (or intolerance), and the established link between obesity and OSA. Some insurers that deny GLP-1s for the obesity indication will approve them for the OSA indication because sleep apnea is categorized differently in their coverage policies.

This isn't a workaround — it's a legitimate clinical application. The FDA approved this indication based on clinical trial data showing that tirzepatide significantly improved sleep apnea severity in addition to causing weight loss.

Beyond Insurance: The Clinical Benefits

The clinical rationale for treating OSA with Zepbound goes beyond gaming insurance codes. Weight loss in patients with OSA directly reduces the severity of airway obstruction. Many patients who lose significant weight on GLP-1 therapy see their AHI scores drop substantially — in some cases below the clinical threshold for OSA, allowing them to reduce or discontinue CPAP therapy.

If you're using a CPAP and struggling with adherence (a common issue — long-term CPAP adherence rates are only about 50%), GLP-1 therapy may provide an alternative or complementary treatment path. Discuss with both your sleep medicine specialist and your GLP-1 prescriber.